A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Trial Profile

A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs BCT 100 (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Bio-Cancer Treatment International
  • Most Recent Events

    • 02 Aug 2017 Last checked against ClinicalTrials.gov record.
    • 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
    • 27 Jul 2017 Status changed from recruiting to discontinued for futility.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top